Abstract
Deregulated activity of transcription factors (TFs) of the Sp/KLF family, like Sp1, Sp3 and Sp4, and consequent over-expression of Sp-regulated genes occur frequently in human cancers. This provides the rationale for development of inhibitors of Sp TFs as cancer therapeutics. Mithramycin A (MTM-A) is a natural polyketide that binds GC-rich DNA sequences, inhibits activity of Sp TFs and exhibits potent antitumor activity in experimental systems. However, clinical use of MTM-A is limited by the severe toxicity of the compound. Here, we studied two MTM-A analogues, which had been generated by genetically engineering of the MTM-A biosynthetic pathway, and evaluated their activity in human prostate cancer in cell cultures and mouse models. The compounds, named MTM-SDK and MTM-SK, were highly effective in vitro inhibiting proliferation of prostate cancer cells and transcription of Sp-regulated genes by blocking binding of Sp proteins to the gene promoters When administered to mice, both compounds were well tolerated with maximum tolerated doses of MTM-SDK and MTM-SK, respectively, 4- and 32- fold higher than MTM-A. After systemic administration, both compounds were cleared rapidly from the bloodstream but maintained plasma levels well above the active concentrations required in vitro for inhibition of Sp TF activity and cell proliferation. Consistently, MTM-SDK and MTM-SK inhibited transcription of Sp-regulated genes in prostate tumor xenografts and exhibited potent antitumor activity in subcutaneous and metastatic tumor xenograft models with no or minimal toxicity. Taken together, these data indicate that MTM-SDK and MTM-SK possess significantly improved pharmacological and toxicological properties compared to MTM-A and represent promising drugs for treatment of advanced prostate cancer.
Highlights
Tumor initiation and progression are mediated by multiple signaling pathways and the therapeutic benefits achievable by targeting individual pathways may be limited [1]
Analysis of the current literature showed that many genes overexpressed in primary and metastatic prostate cancer are regulated by Sp Transcription factors (TFs) and are potential targets of the Mithramycin A (MTM-A) analogues
Applying bioinformatics approaches to publicly available gene expression datasets we found that genes with predicted binding sites for Sp TFs in their promoters were frequently deregulated in prostate tumors both at the early and advanced stages of disease, despite the lack of direct evidence of over-expression of Sp TFs in these tumors (Fig. S1)
Summary
Tumor initiation and progression are mediated by multiple signaling pathways and the therapeutic benefits achievable by targeting individual pathways may be limited [1]. Aberrant expression or activity of the members of the Sp/KLF family of TFs, like Sp1, Sp3 and Sp4, occurs in many human cancers [3] Sp TFs bind to GC-rich DNA elements (GC-box) in gene promoters, interact with components of the basal transcriptional machinery, cooperate with other TFs and are downstream effectors of multiple signaling pathways [3]. MTM-SDK and MTM-SK exhibited greater ability to block Sp1 binding to DNA and cellular uptake compared to MTM-A This led to increased biological activity as inhibitors of Sp regulated gene transcription and proliferation of cancer cells both in vitro and in vivo [27,29].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
